N. Dirks

Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease

M. Rosario, N. Dirks, D. Mould, C. Scholz +3 more

2019Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases0 citations

Semantic Scholar

N. Dirks

Most-cited papers

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease

Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

Transrepression and transactivation potencies of inhaled glucocorticoids.

Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis

P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis

P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

P385 Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease

DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2

P488 Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease

Mo1225 Population Pharmacokinetic Modeling of Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease

Mo1229 Exposure-Response Relationship of Vedolizumab Treatment in Adults With Ulcerative Colitis

Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant

P489 Exposure-response relationship during vedolizumab induction therapy in adults with ulcerative colitis

Mo1231 Vedolizumab Exposure-Response Relationship During Induction Therapy in Adults With Crohn's Disease

Population pharmacokinetics of therapeutic monoclonal antibodies: Examples and estimation method performance differences

Vedolizumab Efficacy Exposure-Response Relationship for Ulcerative Colitis Patients (GEMINI I) Based on Causal Inference Analysis: 640

Sa1868 AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP FOR SUBCUTANEOUS VEDOLIZUMAB MAINTENANCE TREATMENT OF CROHN'S DISEASE: PHARMACOKINETIC FINDINGS FROM VISIBLE 2

Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel Disease

factors of response to prolonged intravenous corticosteroids in patients with acute severe ulcerative colitis

Comparative Performance of Bayesian Markov Chain Monte Carlo and Maximum Likelihood Population Estimation Methods when Applied to Nonlinear Pharmacokinetics of Monoclonal Antibodies